196170.KQ
ALTEOGEN Inc.
KOE · Healthcare · Biotechnology · KR
KRW 283,000.00
−5.19%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 254.0B | 215.9B | 102.9B | 96.5B | 28.8B |
| Cost of Revenue | 31.0B | 39.4B | 38.8B | 65.3B | 19.4B |
| Gross Profit | 223.0B | 176.4B | 64.1B | 31.2B | 9.4B |
| Operating Expenses | |||||
| R&D Expense | 45.1B | 51.5B | 24.6B | 25.3B | 26.6B |
| SG&A Expense | 6.5B | 5.6B | 3.8B | 5.0B | 5.4B |
| General & Admin Expense | 1.7B | 1.8B | 1.1B | 3.0B | 3.6B |
| Selling & Marketing Expense | 4.7B | 3.7B | 2.7B | 2.0B | 1.9B |
| Other Expenses | 68.7B | 12.5B | 10.3B | 10.6B | (747.8K) |
| Total Operating Expenses | 103.2B | 69.5B | 38.7B | 40.9B | 38.8B |
| Cost and Expenses | 134.2B | 109.0B | 77.5B | 106.3B | 58.2B |
| Operating Income (EBIT) | 119.8B | 106.9B | 25.4B | (9.7B) | (29.4B) |
| Non-Operating | |||||
| Interest Income | 13.4B | 11.2B | 7.8B | 5.2B | 3.9B |
| Interest Expense | 13.6B | 11.0B | 674.9M | 670.9M | 425.5M |
| Net Interest Income | (192.9M) | 240.3M | 7.1B | 4.5B | 3.4B |
| Other Non-Op Income/Expense | 96.3B | 55.8B | 11.2B | 6.2B | 19.4B |
| Non-Operating Income (excl Interest) | (59.9B) | (66.8B) | (11.9B) | (6.8B) | (19.8B) |
| EBT (Pre-Tax Income) | 216.1B | 162.7B | 36.6B | (3.6B) | (10.0B) |
| Income Tax Expense | 18.3B | 17.6B | (24.1B) | 17.8M | 108.0M |
| Bottom Line | |||||
| Net Income | 191.3B | 141.7B | 62.3B | (3.4B) | (8.1B) |
| Earnings from Cont. Ops | 197.8B | 145.2B | 60.7B | (3.6B) | (10.1B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 192.9B | 139.8B | 62.3B | (3.4B) | (8.1B) |
| Per Share | |||||
| Basic EPS | ₩3,151 | ₩2,653 | ₩1,172 | (₩65) | (₩159) |
| Diluted EPS | ₩2,658 | ₩2,591 | ₩1,163 | (₩65) | (₩159) |
| Revenue Per Share | ₩3,455 | ₩4,034 | ₩1,936 | ₩1,868 | ₩562 |
| Shares | |||||
| Basic Shares Outstanding | 73.5M | 53.5M | 53.1M | 51.7M | 51.3M |
| Diluted Shares Outstanding | 73.5M | 53.5M | 53.5M | 51.7M | 51.3M |
| Profitability Metrics | |||||
| EBITDA | 135.4B | 179.2B | 40.1B | 440.0M | (6.9B) |
| D&A | 8.9B | 5.5B | 2.9B | 3.3B | 2.7B |
| EBIT | 126.6B | 173.7B | 37.3B | (2.9B) | (9.5B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026